Ronald B Goldberg: Influence Statistics

Ronald B Goldberg

Ronald B Goldberg

University of Miami Miller School of Medicine, FL (R.B.G.). | Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL | University of Miami ...

Ronald B Goldberg: Expert Impact

Concepts for which Ronald B Goldberg has direct influence: Diabetes prevention program , Metabolic syndrome , Insulin resistance , Type 2 diabetes , Lifestyle intervention , 2 diabetes , Type 2 .

Ronald B Goldberg: KOL impact

Concepts related to the work of other authors for which for which Ronald B Goldberg has influence: Metabolic syndrome , Type 2 diabetes , Cardiovascular disease , Insulin resistance , Weight loss , Physical activity , Statin therapy .

KOL Resume for Ronald B Goldberg

Year
2022

University of Miami Miller School of Medicine, FL (R.B.G.).

2021

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami, Miami, Florida, USA.

University of Miami Miller School of Medicine, Miami, FL, USA

2020

Behavioral Medicine Research Center, University of Miami, Coral Gables, FL

Diabetes Research Institute, University of Miami Miller School of Medicine.

2019

University of Miami, Miami, FL

2018

ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative.

From the Department of Medicine (de Groot, Mather), Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, University of Arizona School of Medicine (Marrero), Tucson, Arizona; Biostatistics Center (Mele, Ma), George Washington University, Rockville, Maryland; Department of Psychiatry and Behavioral Neurosciences (Doyle), Loyola University Medical Center, Maywood, Illinois; Camden Clark Memorial Hospital (Schwartz), Parkersburg, West Virginia; University of Miami School of Medicine (Goldberg), Miami, Florida; Department of Family Medicine (Price), University of Colorado Denver School of Medicine and Kaiser Permanente, Denver, Colorado; and National Institute of Diabetes and Digestive and Kidney Diseases (Knowler), Phoenix, Arizona.

Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA

Writing Committee Member

2017

Diabetes Research Institute, University of Miami School of Medicine, Miami, Florida, USA.

Department of Medicine, University of Miami, Miami, Florida.

2016

MedStar Health Research Institute (V.R.A.), Hyattsville, Maryland 20782; George Washington University (S.L.E., M.G.T.), Rockville, MD 20852; University of Miami (R.B.G.), Miami, Florida 33146; National Institute of Diabetes and Digestive and Kidney Diseases (W.C.K.), Phoenix, Arizona 85014; University of Washington (S.M.M.), Seattle, Washington 98185; University of Pittsburgh (T.J.O.), Pittsburgh, Pennsylvania 15260; Pennington Biomedical Research Institute (G.A.B.), Baton Rouge, Louisiana 70808; University of New Mexico (D.S.S.), Albuquerque, New Mexico 87131; Washington University School of Medicine (N.H.W.), St. Louis, Missouri 63110; and Albert Einstein College of Medicine (J.P.C.), Bronx, New York 10461.

Diabetes Research Institute, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, FL, USA

2015

University of Miami Department of Medicine Miami FL USA

2014

Diabetes Prevention Program Data Coordinating Center, The Biostatistics Center, George Washington University, 6110 Executive Blvd, Suite 750, 20852, Rockville, MD, USA

University of Miami Miller School of Medicine, Miami, FL

2013

Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Diabetes Research Institute, University of Miami, Miller School of Medicine, Miami, FL, USA

2, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida

2012

Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Miami, FL 33136, USA

The Diabetes Research Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, United States of America

Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL.

2011

From the Department of Neurology (H.G., C.B.W., R.L.S., T.R.) and the Diabetes Research Institute (R.G., A.M.), Miller School of Medicine, University of Miami, Miami, FL; the Department of Neurobiology (C.S., M.C.), Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; and the Department of Neurology (M.S.V.E.), Columbia University College of Physicians and Surgeons, New York, NY.

Division of Endocrinology, Diabetes, and Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA

2010

Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine and Lipid Disorders Unit, Diabetes Research Institute, Miami, FL

Departments of Neurology (Drs Rundek, Gardener, Wright, and Sacco), Medicine (Dr Goldberg), and Epidemiology, Human Genetics (Dr Sacco), Miller School of Medicine, University of Miami, Miami, Florida

2009

Division of Endocrinology & Metabolism, School of Medicine, University of Miami, Miami, FL;

Diabetes Prevention Program Coordinating Center, George Washington University, Rockville, Maryland.

2008

Department of Preventive Medicine, Stony Brook University Medical Center, Stony Brook, NY

Diabetes Research Institute, University of Miami, Miller School of Medicine, Miami, FL 33136, USA

University of Miami Behavioral Medicine Research Center, Coral Gables, FL

2007

1Department of Endocrinology and Metabolism, Veterans Affairs Hospital and Indiana University, Indianapolis, Indiana 2Department of Endocrinology and General Medicine, University of North Carolina, Chapel Hill, North Carolina 3Department of Endocrinology, Metabolism and Diabetes, University of Miami, Miami, Florida 4International Diabetes Center, Park Nicollet Institute, Minneapolis, Minnesota 5Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 6Takeda Pharmaceuticals North America, Lincolnshire, Illinois 7Takeda Global Research and Development, Lincolnshire, Illinois

Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.

2006

Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, 1450 NW 10th Avenue, 33136, Miami, FL, USA

From the University of Miami School of Medicine,Miami,Florida.

Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, Fla

2005

From the Department of Psychology, University of Miami, Coral Gables, FL (B.–J.S., M.M.L., N.S.); Department of Medicine, Division of Endocrinology, University of Miami School of Medicine, Coral Gables, FL (R.B.G.)

1Division of Endocrinology, Metabolism, and Diabetes, University of Miami School of Medicine, Miami, Florida 2International Diabetes Center, Park Nicollet Institute, Minneapolis, Minnesota 3Division of Endocrinology and Metabolism, Department of Veterans Affairs and the Indiana University School of Medicine, Indianapolis, Indiana 4Divisions of Endocrinology and of General Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 5Lilly Research Laboratories, Eli Lilly, Indianapolis, Indiana 6Takeda Pharmaceuticals North America, Lincolnshire, Illinois 7Takeda Global Research and Development Center, Lincolnshire, Illinois

University of Miami Miller School of Medicine, 1450 NW 10th Avenue, Diabetes Research Institute #2054, Miami, FL 33136, USA

2004

Division of Endocrinology, Department of Medicine, Diabetes and Metabolism, Diabetes Research Institute, University of Miami School of Medicine, USA

Prominent publications by Ronald B Goldberg

KOL-Index: 18983 . BACKGROUND: Effective prevention is needed to combat the worldwide epidemic of type 2 diabetes. We investigated the long-term extent of beneficial effects of lifestyle intervention and metformin on diabetes prevention, originally shown during the 3-year Diabetes Prevention Program (DPP), and assessed whether these interventions reduced diabetes-associated microvascular ...
Known for Lifestyle Intervention | Microvascular Complications | Metformin Placebo | Dpp Outcomes Study
KOL-Index: 17996 . OBJECTIVE: Type 1 diabetes mellitus (T1D) patients have an increased risk of cardiovascular disease despite high levels of high-density lipoproteins (HDL). Apolipoprotein M (apoM) and its ligand sphingosine 1-phospate (S1P) exert many of the anti-inflammatory effects of HDL. We investigated whether apoM and S1P are altered in T1D and whether apoM and S1P are important for HDL functionality ...
Known for Apom S1p | Type 1 | Hdl Particles | Cardiovascular Disease
KOL-Index: 17261 . BACKGROUND: In the 2.8 years of the Diabetes Prevention Program (DPP) randomised clinical trial, diabetes incidence in high-risk adults was reduced by 58% with intensive lifestyle intervention and by 31% with metformin, compared with placebo. We investigated the persistence of these effects in the long term. METHODS: All active DPP participants were eligible for continued follow-up. 2766 ...
Known for Diabetes Incidence | Lifestyle Intervention Metformin | Weight Loss | 10 Years
KOL-Index: 16245 . OBJECTIVE: Associated with insulin resistance in type 2 diabetes are increased serum triglycerides, decreased HDL cholesterol, and a predominance of large VLDL, small LDL, and small HDL particles. The comparative effects of thiazolidinedione insulin sensitizers on serum lipoprotein particle concentrations and sizes in type 2 diabetes are not known. We studied the effects of pioglitazone ...
Known for 2 Diabetes | Hdl Lipoproteins | Pio Treatment | Insulin Resistance
KOL-Index: 15453 . BACKGROUND: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. OBJECTIVE: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the ...
Known for Diabetes Prevention Program | Intensive Lifestyle Intervention | Metabolic Syndrome | Metformin Therapy
KOL-Index: 15253 . BACKGROUND: In people without diabetes, approximately 50% of daily insulin secretion is basal and the remainder is postprandial. Hence, it would be expected that insulin replacement therapy in a 50/50 ratio with each meal would mimic physiologic insulin secretion better than treatment with once-daily basal insulin in patients with diabetes mellitus. Using lispro mix (LM) 50/50 before meals ...
Known for 2 Diabetes | Basal Insulin | Blood Glucose | Target Hba1c
KOL-Index: 14433 . CONTEXT: Vitamin B12 deficiency may occur with metformin treatment, but few studies have assessed risk with long-term use. OBJECTIVE: To assess the risk of B12 deficiency with metformin use in the Diabetes Prevention Program (DPP)/DPP Outcomes Study (DPPOS). DESIGN: Secondary analysis from the DPP/DPPOS. Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin ...
Known for B12 Deficiency | Term Metformin | Diabetes Prevention | 5 Years
KOL-Index: 13790 . OBJECTIVE: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either retrospective chart reviews or clinical trials not rigorously controlled for concomitant glucose- and lipid-lowering therapies. This study examines the lipid and glycemic effects of pioglitazone and ...
Known for Pioglitazone Rosiglitazone | Hdl Cholesterol | Type 2 Diabetes | Glycemic Effects
KOL-Index: 13540 . OBJECTIVE: To compare the efficacy and safety of the recommended usual starting and next highest doses of ezetimibe/ simvastatin and atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. PATIENTS AND METHODS: This double-blind, multicenter study (June 22 to December 7, 2005) consisted of adult patients randomized to the recommended usual starting ...
Known for Ezetimibe Simvastatin | 2 Diabetes | Atorvastatin Patients | Hdl Cholesterol
KOL-Index: 13134 . OBJECTIVE: To evaluate the efficacy and safety of initial combination therapy with metformin plus colesevelam in patients with early type 2 diabetes. METHODS: In this 16-week, randomized, double-blind, placebo-controlled study, adults with type 2 diabetes (hemoglobin A1c [A1C] values of 6.5% to 10.0%) and hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] levels > or =100 ...
Known for 2 Diabetes | Initial Combination Therapy | Metformin Colesevelam | Early Type
KOL-Index: 12815 . BACKGROUND: Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM). METHODS: This 26-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted between August 2004 and July 2006 at 54 sites ...
Known for Colesevelam Hydrochloride | Diabetes Mellitus | Type 2 | Glucose Levels Patients
KOL-Index: 12335 . OBJECTIVE: Restoration of normal glucose regulation (NGR) in people with prediabetes significantly decreases the risk of future diabetes. We sought to examine whether regression to NGR is also associated with a long-term decrease in cardiovascular disease (CVD) risk. RESEARCH DESIGN AND METHODS: The Framingham (2008) score (as an estimate of the global 10-year CVD risk) and individual CVD ...
Known for Cardiovascular Risk | Normal Glucose Regulation | Diabetes Prevention Program | Regression Ngr
KOL-Index: 12227 . OBJECTIVES: This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. BACKGROUND: During a 3-year follow-up in 3,414 patients with established CV disease and ...
Known for Metabolic Syndrome | Cardiovascular Events | Atherothrombosis Intervention | Low Hdl
KOL-Index: 12082 . Increases in subclinical inflammation (C-reactive protein [CRP]) and impaired coagulation have been associated with increased obesity and insulin resistance. Only a few small studies have examined the effect of lifestyle changes, such as weight loss, increased physical activity, and insulin-sensitizing intervention on inflammation and coagulation. The Diabetes Prevention Program (DPP) ...
Known for Impaired Glucose Tolerance | Lifestyle Metformin | Crp Women | Increased Physical Activity
KOL-Index: 11998 . OBJECTIVE: To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of ...
Known for Diabetes Prevention Program | Adiponectin Levels | Lifestyle Metformin | Hazard Ratio

Key People For Diabetes Prevention Program

Top KOLs in the world
#1
William C Knowler
pima indians type 2 diabetes weight loss
#2
Richard F Hamman
type 1 diabetes san luis valley insulin sensitivity
#3
Elizabeth L Barrett‐Connor
rancho bernardo study postmenopausal women cognitive function
#4
Sarah E Fowler
rheumatoid arthritis diabetes prevention program pulmonary embolism
#5
David Matthew Nathan
type 2 diabetes insulin resistance cardiovascular disease
#6
John M Lachin
type 1 diabetes cardiovascular disease complications trial

University of Miami Miller School of Medicine, FL (R.B.G.). | Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL | University of Miami Miller School of Medicine, Miami, Florida, USA. | Division of Endocrinology, Dia